This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Patient Safety/ Medical Error  • Prognosis/ Outcomes  • Psoriasis  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic

Bronwyn Williams, BSc(Hons); Daina Vanags, PhD; Stephen Hall, FRACP; Chris McCormack, FACD; Peter Foley, FACD; Julissa Weiss, BSc; Barbara Johnson, PhD; Eicke Latz, MD, PhD; Dennis Feeney, MSc, PhD

Arch Dermatol. 2008;144(5):683-685.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chaperonin 10 is a highly conserved protein that is essential in protein folding. Recombinant chaperonin 10 (Cpn10) (1 amino acid different to native chaperonin 10) and has immunomodulatory function in vitro and in vivo.^1-2 Treatment with Cpn10 improved clinical disease activity in patients with rheumatoid arthritis and downregulated cytokine responses of immune cells to cellular stimuli.² An exploratory study of Cpn10 treatment for chronic plaque psoriasis is reported.

Methods

Forty patients were screened, and 24 (aged 18 to 75 years) with plaque psoriasis for at least 6 months prior to screening, 10% or greater of the body surface area affected by plaque psoriasis, a Psoriasis Area and Severity Index (PASI) score of 12 or higher (severe psoriasis), and a Physician's Global Assessment . . . [Full Text of this Article]

Results

Comment

AUTHOR INFORMATION